Clinical Trial Update: Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of ziftomenib for patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia who are not eligible …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Kmt2a-rearranged Acute Myeloid Leukemia
• Npm1-mutated Acute Myeloid Leukemia

Drugs mentioned

• Ziftomenib (ziftomenib)

Snippet

Sponsor: Uma Borate | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING